301080 Stock Overview
Engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Acrobiosystems Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥48.94 |
| 52 Week High | CN¥52.60 |
| 52 Week Low | CN¥31.30 |
| Beta | 0.76 |
| 1 Month Change | 13.81% |
| 3 Month Change | 19.72% |
| 1 Year Change | 11.68% |
| 3 Year Change | -56.51% |
| 5 Year Change | n/a |
| Change since IPO | -56.52% |
Recent News & Updates
Recent updates
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think
Nov 06
Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%
Oct 01Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price
Jul 15AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear
May 02Shareholder Returns
| 301080 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | 0.9% |
| 1Y | 11.7% | -14.0% | 11.5% |
Return vs Industry: 301080 exceeded the CN Biotechs industry which returned -14% over the past year.
Return vs Market: 301080 matched the CN Market which returned 11.5% over the past year.
Price Volatility
| 301080 volatility | |
|---|---|
| 301080 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 301080 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301080's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 839 | Yiding Chen | www.acrobiosystems.cn |
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization.
Acrobiosystems Co.,Ltd. Fundamentals Summary
| 301080 fundamental statistics | |
|---|---|
| Market cap | CN¥5.86b |
| Earnings (TTM) | CN¥108.93m |
| Revenue (TTM) | CN¥594.56m |
53.8x
P/E Ratio9.9x
P/S RatioIs 301080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301080 income statement (TTM) | |
|---|---|
| Revenue | CN¥594.56m |
| Cost of Revenue | CN¥89.72m |
| Gross Profit | CN¥504.84m |
| Other Expenses | CN¥395.91m |
| Earnings | CN¥108.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 21, 2025
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 84.91% |
| Net Profit Margin | 18.32% |
| Debt/Equity Ratio | 2.0% |
How did 301080 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield99%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/27 19:14 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acrobiosystems Co.,Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jiaying Fu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |